Compare Stocks: HALO, NTRA, RVMD, and BIIB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$209.83 -0.4%	$203.76	$131.52 ▼ $219.72	$31.00B	0.17	1.01 million shs	554,425 shs
HALO Halozyme Therapeutics	$98.66 -2.0%	$79.66	$61.22 ▼ $104.78	$11.20B	0.85	2.33 million shs	1.66 million shs
NTRA Natera	$309.93 -0.3%	$263.76	$156.71 ▼ $326.03	$44.67B	1.51	1.29 million shs	1.27 million shs
RVMD Revolution Medicines	$203.71 +0.8%	$181.62	$35.42 ▼ $208.76	$43.66B	1.39	1.77 million shs	784,220 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	+0.91%	+0.44%	+8.75%	+55.19%
HALO Halozyme Therapeutics	0.00%	-4.33%	+27.24%	+46.99%	+51.48%
NTRA Natera	0.00%	-3.78%	+14.86%	+66.31%	+96.53%
RVMD Revolution Medicines	0.00%	-0.70%	+13.69%	+39.85%	+465.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$209.83 -0.4%	$203.76	$131.52 ▼ $219.72	$31.00B	0.17	1.01 million shs	554,425 shs
HALO Halozyme Therapeutics	$98.66 -2.0%	$79.66	$61.22 ▼ $104.78	$11.20B	0.85	2.33 million shs	1.66 million shs
NTRA Natera	$309.93 -0.3%	$263.76	$156.71 ▼ $326.03	$44.67B	1.51	1.29 million shs	1.27 million shs
RVMD Revolution Medicines	$203.71 +0.8%	$181.62	$35.42 ▼ $208.76	$43.66B	1.39	1.77 million shs	784,220 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	+0.91%	+0.44%	+8.75%	+55.19%
HALO Halozyme Therapeutics	0.00%	-4.33%	+27.24%	+46.99%	+51.48%
NTRA Natera	0.00%	-3.78%	+14.86%	+66.31%	+96.53%
RVMD Revolution Medicines	0.00%	-0.70%	+13.69%	+39.85%	+465.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.58	Moderate Buy	$227.07	8.22% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-7.56% Downside
NTRA Natera	2.82	Moderate Buy	$319.38	3.05% Upside
RVMD Revolution Medicines	2.91	Moderate Buy	$161.79	-20.58% Downside

Current Analyst Ratings Breakdown

Latest HALO, NTRA, RVMD, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	BIIB Biogen	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/13/2026	NTRA Natera	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$315.00 ➝ $365.00
8/12/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/12/2026	NTRA Natera	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$305.00 ➝ $350.00
8/12/2026	NTRA Natera	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $360.00
8/12/2026	NTRA Natera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$249.00 ➝ $363.50
8/11/2026	RVMD Revolution Medicines	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$210.00 ➝ $231.00
8/10/2026	NTRA Natera	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$355.00
8/10/2026	RVMD Revolution Medicines	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$220.00
8/7/2026	NTRA Natera	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$325.00 ➝ $340.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.89B	3.13	$22.64 per share	9.27	$127.56 per share	1.64
HALO Halozyme Therapeutics	$1.40B	8.02	$4.77 per share	20.68	$1.26 per share	78.30
NTRA Natera	$2.71B	16.50	N/A	N/A	$12.64 per share	24.52
RVMD Revolution Medicines	$11.58M	3,770.57	N/A	N/A	$12.16 per share	16.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.29B	$5.65	37.14	12.80	6.48	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	29.45	10.65	0.40	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	30,993.00	N/A	-7.11%	-11.38%	-7.87%	N/A
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)

Latest HALO, NTRA, RVMD, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.39	1.87	1.26
HALO Halozyme Therapeutics	13.50	2.71	2.31
NTRA Natera	N/A	3.00	2.83
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
HALO Halozyme Therapeutics	97.79%
NTRA Natera	99.90%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.25%
HALO Halozyme Therapeutics	2.50%
NTRA Natera	5.05%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
HALO Halozyme Therapeutics	390	113.50 million	110.66 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
RVMD Revolution Medicines	250	214.34 million	198.05 million	Optionable

HALO, NTRA, RVMD, and BIIB Headlines

Recent News About These Companies

State of Wyoming Buys Shares of 9,446 Revolution Medicines, Inc. $RVMD

4 hours ago | marketbeat.com

S&CO Inc. Invests $6.40 Million in Revolution Medicines, Inc. $RVMD

4 hours ago | marketbeat.com

Revolution Medicines (RVMD) Receives a Buy from Truist Financial

August 12, 2026 | theglobeandmail.com

Why Revolution Medicines May Be Big Pharma's Next Takeover Target

August 12, 2026 | 247wallst.com

Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD

August 12, 2026 | marketbeat.com

Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD

August 12, 2026 | marketbeat.com

Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach

August 12, 2026 | finance.yahoo.com

Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Should You Buy?

August 11, 2026 | marketbeat.com

Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD

August 11, 2026 | marketbeat.com

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

August 10, 2026 | businesswire.com

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

August 9, 2026 | theglobeandmail.com

Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD

August 9, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $240.00

August 9, 2026 | americanbankingnews.com

Sei Investments Co. Cuts Holdings in Revolution Medicines, Inc. $RVMD

August 8, 2026 | marketbeat.com

'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug

August 7, 2026 | bizjournals.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

August 7, 2026 | theglobeandmail.com

High Risk, High Reward: Inside The Revolution Medicines Bull Case

August 7, 2026 | seekingalpha.com

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

August 6, 2026 | zacks.com

Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00

August 6, 2026 | marketbeat.com

Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

August 6, 2026 | marketbeat.com

Revolution Medicines Q2 Earnings Call Highlights

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HALO, NTRA, RVMD, and BIIB Company Descriptions

Biogen NASDAQ:BIIB

$209.83 -0.82 (-0.39%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$209.81 -0.02 (-0.01%)

As of 08/14/2026 07:37 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Halozyme Therapeutics NASDAQ:HALO

$98.66 -2.01 (-2.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$98.08 -0.58 (-0.59%)

As of 08/14/2026 07:34 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Natera NASDAQ:NTRA

$309.93 -0.85 (-0.27%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$308.80 -1.13 (-0.36%)

As of 08/14/2026 07:59 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines NASDAQ:RVMD

$203.71 +1.71 (+0.85%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$203.42 -0.29 (-0.14%)

As of 08/14/2026 07:34 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HALO, NTRA, RVMD, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HALO, NTRA, RVMD, and BIIB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HALO, NTRA, RVMD, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HALO, NTRA, RVMD, and BIIB Company Descriptions

Biogen NASDAQ:BIIB

Halozyme Therapeutics NASDAQ:HALO

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HALO, NTRA, RVMD, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HALO, NTRA, RVMD, and BIIB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HALO, NTRA, RVMD, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HALO, NTRA, RVMD, and BIIB Company Descriptions

Biogen NASDAQ:BIIB

Halozyme Therapeutics NASDAQ:HALO

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools